Stock Yards Bank & Trust Co. increased its position in Novo Nordisk A/S (NYSE:NVO) by 0.6% during the third quarter, Holdings Channel reports. The firm owned 245,000 shares of the company’s stock after buying an additional 1,579 shares during the period. Novo Nordisk A/S comprises about 1.4% of Stock Yards Bank & Trust Co.’s investment portfolio, making the stock its 26th largest position. Stock Yards Bank & Trust Co.’s holdings in Novo Nordisk A/S were worth $10,189,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Investment Centers of America Inc. boosted its stake in shares of Novo Nordisk A/S by 0.4% in the second quarter. Investment Centers of America Inc. now owns 6,713 shares of the company’s stock worth $363,000 after buying an additional 28 shares during the period. Bremer Trust National Association boosted its stake in shares of Novo Nordisk A/S by 0.5% in the third quarter. Bremer Trust National Association now owns 7,928 shares of the company’s stock worth $330,000 after buying an additional 36 shares during the period. Redmond Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 0.3% in the second quarter. Redmond Asset Management LLC now owns 16,044 shares of the company’s stock worth $863,000 after buying an additional 44 shares during the period. Cape ANN Savings Bank boosted its stake in shares of Novo Nordisk A/S by 1.1% in the second quarter. Cape ANN Savings Bank now owns 4,748 shares of the company’s stock worth $255,000 after buying an additional 50 shares during the period. Finally, Martin Investment Management LLC boosted its stake in shares of Novo Nordisk A/S by 1.7% in the second quarter. Martin Investment Management LLC now owns 4,895 shares of the company’s stock worth $263,000 after buying an additional 80 shares during the period. 7.34% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Shares of Novo Nordisk A/S (NYSE:NVO) traded up 0.37% during mid-day trading on Tuesday, hitting $32.66. The stock had a trading volume of 2,717,079 shares. The company has a market cap of $82.52 billion, a P/E ratio of 15.58 and a beta of 0.84. Novo Nordisk A/S has a 1-year low of $30.89 and a 1-year high of $59.00. The firm’s 50 day moving average price is $36.32 and its 200 day moving average price is $47.04.

TRADEMARK VIOLATION WARNING: This article was first published by Financial Market News and is the sole property of of Financial Market News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright laws. The correct version of this article can be viewed at http://www.financial-market-news.com/novo-nordisk-as-nvo-stake-boosted-by-stock-yards-bank-trust-co/1208721/.

A number of equities research analysts recently commented on the company. Bank of America Corp. set a $57.00 price objective on Novo Nordisk A/S and gave the stock a “hold” rating in a research note on Saturday, September 17th. Citigroup Inc. reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research note on Wednesday, August 3rd. Pacific Crest raised Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Tuesday, September 13th. DNB Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, October 31st. Finally, Deutsche Bank AG raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Monday, September 12th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $61.33.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

5 Day Chart for NYSE:NVO

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.